News JPM: Illumina launches 'unprecedented' disease biology atlas Illumina says its new Billion Cell Atlas can be used to identify and validate drug targets and train AI models used in drug discovery.
R&D JPM: The calm before the storm for radiotherapeutics Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.
R&D Is this the year for precision psychology? With Amit Etkin At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.
News JPM: Anthropic reveals its answer to ChatGPT for Health Anthropic has launched Claude for Healthcare, a suite of AI tools designed for health systems, payers, and patients.
News JPM: Is the UK's clinical trials sector turning a corner? New data from the UK medicines regulator has shown an increase in clinical trial activity in the country, after years of decline.
News NVIDIA announces Lilly, Thermo Fisher collaborations at JPM Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, including a billion dollar partnership with Eli Lilly.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.